Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | HMGCR | P04035 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6931356 | 0.82 | CACNA2D1 (0.50) | CSNK1ECACNA2D1CACNB2CACNA1CHMGCR | |
| SCHEMBL12055532 | 0.81 | CSNK1E (0.52) | CSNK1EHMGCRKCNH2ALDH1A1SPHK1 | |
| SCHEMBL12035759 | 0.80 | SPHK1 (0.50) | HMGCRHTTSPHK1KDM4E | |
| SCHEMBL12035756 | 0.79 | ABCG2 (0.40) | CSNK1ECACNA2D1CACNB2CACNA1CHMGCR | |
| SCHEMBL31682160 | 0.78 | ALDH1A1 (0.42) | CSNK1ECACNA2D1CACNB2CACNA1CKCNH2 | |
| SCHEMBL28742961 | 0.77 | HMGCR (0.52) | CACNA2D1CACNB2CACNA1CHMGCRHTT | |
| SCHEMBL30040696 | 0.77 | HMGCR (0.52) | CACNA2D1CACNB2CACNA1CHMGCRHTT | |
| SCHEMBL31682124 | 0.77 | CSNK1E (0.45) | CSNK1ECACNA2D1CACNB2CACNA1CHMGCR | |
| SCHEMBL31682136 | 0.77 | ALDH1A1 (0.46) | CACNA2D1CACNB2CACNA1CKCNH2NAAA | |
| SCHEMBL15283856 | 0.75 | NAAA (0.42) | CSNK1ECACNA2D1CACNB2CACNA1CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859615-B2 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-14 | — | — | US | disclosed |
| US-8859615-B2 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-14 | — | — | US | disclosed |
| US-8859615-B2 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-14 | — | — | US | disclosed |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2010025272-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | TUBA1C, TUBB1, TOP1 | CSNK1E 830/4885CACNA2D1 4168/4885CACNB2 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.